Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Calcineurin is a Ca 2+ -calmodulin-activated serine/threonine-specific protein phosphatase that governs multiple aspects of fungal physiology, including cation homeostasis, morphogenesis, antifungal drug susceptibility, and virulence. Growth of Candida albicans planktonic cells is sensitive to the calcineurin inhibitors FK506 and cyclosporine A (CsA) in combination with the azole antifungal fluconazole. This drug synergism is attributable to two effects: first, calcineurin inhibitors render fluconazole fungicidal rather than simply fungistatic, and second, membrane perturbation by azole inhibition of ergosterol biosynthesis increases intracellular calcineurin inhibitor concentrations. C. albicans cells in biofilms are up to 1,000-fold more resistant to fluconazole than planktonic cells. In both in vitro experiments and in an in vivo rat catheter model, C. albicans cells in biofilms were resistant to individually delivered fluconazole or calcineurin inhibitors but exquisitely sensitive to the combination of FK506-fluconazole or CsA-fluconazole. C. albicans strains lacking FKBP12 or expressing a dominant FK506-resistant calcineurin mutant subunit (Cnb1-1) formed biofilms that were resistant to FK506-fluconazole but susceptible to CsA-fluconazole, demonstrating that drug synergism is mediated via direct calcineurin inhibition. These findings reveal that calcineurin contributes to fluconazole resistance of biofilms and provide evidence that synergistic drug combinations may prove efficacious as novel therapeutic interventions to treat or prevent biofilms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 and calcineurin are well known to affect fungal drug responses, including the cidality of azoles 26,32,42,43,70,71 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous findings have indicated little or no effect for treatment of mature biofilms when FLU is used in combination with other antifungals, including AmB and CAS [10], whereas synergistic effects (similar to the enhanced effect reported in this study) have been observed when FLU is combined with calcium channel inhibitors [11] and doxycycline [12], among others.”
From In vitro analysis of flufenamic acid activity against Candida albicans biofilms (2014) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms
Ramage, G., Vande Walle, K., Wickes, B. L., & López-Ribot, J. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2475-2479.2001 · Cited by 753
Mukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511 · cited 2×
“albicans biofilm resistance to fluconazole is considered multifactorial, encompassing contributions of cell density, impermeability of drugs through the extracellular matrix, activation of multidrug efflux pumps, increases in cellular -1,3 glucan levels, and decreases in sterol levels (5, 20, 22, 26).”
BackgroundNosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502 · cited 1×
“albicans can enter the bloodstream to cause serious systemic invasive disease (6, 38).”
BackgroundPutative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-06 · Cited by 407 · cited 3×
“A recent report also demonstrated that cell wall -1,3 glucan levels contribute to biofilm resistance to fluconazole (22).”
BackgroundMethodSelf-citationBaillie, G. S. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.397 · Cited by 389
Andes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., & Pitula, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.6023-6031.2004 · Cited by 389
Self-citationSanglard, D., Ischer, F., Marchetti, O., Entenza, J., & Bille, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03495.x · Cited by 350
Calcineurin is essential for survival during membrane stress in Candida albicans
Cruz, M. C., Goldstein, A. L., Blankenship, J. R., Del Poeta, M., Davis, D., Cardenas, M. E., Perfect, J. R., McCusker, J. H., & Heitman, J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.546 · Cited by 342 · cited 15×
“albicans, calcineurin is required for survival in serum, virulence, and resistance to azole antifungals, in part via its downstream target, Crz1 (7, 9, 11, 15).”
BackgroundInfluentialSelf-citationBiochemical Targets for Antifungal Azole Derivatives: Hypothesis on the Mode of Action
Vanden Bossche, H. (1985) · Current Topics in Medical Mycology · doi:10.1007/978-1-4613-9547-8_12 · Cited by 321
Cited by
Items 101–200 of 228
Hayama, K., Ishibashi, H., Ishijima, S. A., Niimi, K., Tansho, S., Ono, Y., Monk, B. C., Holmes, A. R., Harding, D. R. K., Cannon, R. D., et al. (2012) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2011.02490.x · Cited by 34
Signaling cascades as drug targets in model and pathogenic fungi.
Bastidas, R. J., Reedy, J. L., Morales-Johansson, H., Heitman, J., & Cardenas, M. E. (2008) · PubMed · Cited by 46
Self-citationTebbets, B., Stewart, D. A., Lawry, S. M., Nett, J. E., Nantel, A., Andes, D. R., & Klein, B. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036021 · Cited by 36
Self-citationHuang, M.-C., Shen, M., Huang, Y.-J., Lin, H.-C., & Chen, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020434 · Cited by 36
Structure-guided approaches to targeting stress responses in human fungal pathogens
LeBlanc, E. V., Polvi, E. J., Veri, A. O., Privé, G. G., & Cowen, L. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.013731 · Cited by 36
Pulmonary biofilm-based chronic infections and inhaled treatment strategies
Ding, L., Wang, J., Cai, S., Smyth, H. D. C., & Cui, Z. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120768 · Cited by 36
Combinatorial drug approaches to tackleCandida albicansbiofilms
Cremer, K. D., Staes, I., Delattin, N., Cammue, B. P. A., Thevissen, K., & Brucker, K. D. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1056162 · Cited by 35
Xu, J., Liu, R., Sun, F., An, L., Shang, Z., Kong, L., & Yang, M. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00211 · Cited by 35
Tacrolimus Increases the Effectiveness of Itraconazole and Fluconazole against Sporothrix spp.
Borba-Santos, L. P., de Sá, L. F. R., Ramos, J. A., Rodrigues, A. M., Camargo, Z. P. D., Rozental, S., & Ferreira‐Pereira, A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01759 · Cited by 32
Growth of Aspergillus fumigatus in Biofilms in Comparison to Candida albicans
Subroto, E., van Neer, J., Valdes, I. D., & de Cock, H. (2022) · Journal of Fungi · doi:10.3390/jof8010048 · Cited by 33
Synthesis and evaluation of novel furanones as biofilm inhibitors in opportunistic human pathogens
Gómez, A.-C., Lyons, T., Mamat, U., Yero, D., Bravo, M., Daura, X., Elshafee, O., Brunke, S., Gahan, C. G. M., O’Driscoll, M., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114678 · Cited by 30
Alex, D., Gay‐Andrieu, F., May, J. P., Thampi, L. M., Dou, D., Mooney, A., Groutas, W. C., & Calderone, R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00477-12 · Cited by 28
Future therapies targeted towards eliminatingCandidabiofilms and associated infections
Bandara, N., Matsubara, V. H., & Samaranayake, L. P. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1268530 · Cited by 39
Potent Antifungal Synergy of Phthalazinone and Isoquinolones with Azoles Against Candida albicans
Mood, A. D., Premachandra, I. D. U. A., Hiew, S. C., Wang, F., Scott, K. A., Oldenhuis, N. J., Liu, H., & Vranken, D. L. V. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00355 · Cited by 31
In vitro analysis of flufenamic acid activity against Candida albicans biofilms
Chavez-Dozal, A. A., Jahng, M., Rane, H. S., Asare, K., Kulkarny, V. V., Bernardo, S. M., & Lee, S. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.08.018 · Cited by 26
Antifungal adjuvants: Preserving and extending the antifungal arsenal
Butts, A., Palmer, G. E., & Rogers, P. D. (2017) · Virulence · doi:10.1080/21505594.2016.1216283 · Cited by 26
The Hsp90 Co-chaperones Sti1, Aha1, and P23 Regulate Adaptive Responses to Antifungal Azoles
Gu, X., Xue, W., Yin, Y., Liu, H., Li, S., & Sun, X. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01571 · Cited by 26
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2017) · ASM Press eBooks · doi:10.1128/9781555819583.ch44 · Cited by 27
Antifungal activity of immunosuppressants used alone or in combination with fluconazole
Zhang, M., Yang, X., Wang, D., Yu, C., & Sun, S. (2018) · Journal of Applied Microbiology · doi:10.1111/jam.14126 · Cited by 27
Biosynthesis of Nonimmunosuppressive FK506 Analogues with Antifungal Activity
Beom, J. Y., Jung, J. A., Lee, K.-T., Hwangbo, A., Song, M., Lee, Y., Lee, S. J., Oh, J. H., Ha, S., Nam, S., et al. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00144 · Cited by 25
Chen, E., Choy, M. S., Petrényi, K., Kónya, Z., Erdődi, F., Dombrádi, V., Peti, W., & Page, R. (2016) · mBio · doi:10.1128/mbio.00872-16 · Cited by 25
Cha, H., Won, D., Kang, S., Kim, E.-S., Lee, K.-A., Lee, W.-J., Lee, K.-T., & Bahn, Y.-S. (2025) · PLOS Pathogens · doi:10.1371/journal.ppat.1013363 · Cited by 24
“In C. albicans , FK506 and CsA improve FLC efficacy by impairing stress adaptation mechanisms [37,38].”
Old and new strategies in therapy and diagnosis against fungal infections
Vanzolini, T., & Magnani, M. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12884-8 · Cited by 31
In Vitro Interactions of Antifungal Agents and Tacrolimus against Aspergillus Biofilms
Gao, L., & Sun, Y. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01510-15 · Cited by 24
Hsp21 Potentiates Antifungal Drug Tolerance in Candida albicans
Mayer, F. L., Wilson, D., & Hube, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060417 · Cited by 26
Liu, H., Wang, L., Li, Y., Liu, J., An, M., Zhu, S.-L., Cao, Y., Jiang, Z., Zhao, M.-Z., Cai, Z. J., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300332 · Cited by 24
Li, H., Chen, Z., Zhang, W., Gao, Y., Zhang, X., & Sun, S. (2014) · Journal of Medical Microbiology · doi:10.1099/jmm.0.081760-0 · Cited by 26
In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans
Guo, N., Ling, G., Liang, X., Jin, J., Fan, J., Qiu, J., Song, Y., Huang, N., Wu, X., Wang, X., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01935.x · Cited by 26
Schwarz, P., Schwarz, P., Felske-Zech, H., & Dannaoui, É. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz102 · Cited by 23
Actividad de la micafungina contra las biopelículas de Candida
Quindós, G., Villar-Vidal, M., & Eraso, E. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70008-7 · Cited by 27
Su, S., Yan, H., Li, M., Wang, H., Chen, X., Shi, J., & Sun, S. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1941868 · Cited by 27
Modeling of Fungal Biofilms Using a Rat Central Vein Catheter
Nett, J. E., Marchillo, K., & Andes, D. R. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-539-8_40 · Cited by 21
Self-citationKubiça, T. F., Denardi, L. B., de Azevedo, M. I., Oliveira, V., Severo, L. C., Santúrio, J. M., & Alves, S. H. (2016) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2016.08.008 · Cited by 21
Mechanisms of Azole Potentiation: Insights from Drug Repurposing Approaches
Xiong, J., Lu, H., & Jiang, Y. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00657 · Cited by 20
Azole potentiation in Candida species
Stenkiewicz-Witeska, J., & Ene, I. V. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011583 · Cited by 22
Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations
Joice, A. C., Yang, S., Farahat, A. A., Meeds, H. L., Feng, M., Li, J., Boykin, D. W., Wang, M. Z., & Werbovetz, K. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01129-17 · Cited by 22
Zheng, Q., Zhang, Y., Ren, Y., Zhao, Z., Hua, S., Li, J., Wang, H., Ye, C., Kim, A. D., Wang, L., et al. (2020) · Xenotransplantation · doi:10.1111/xen.12655 · Cited by 19
Ibrahim, N. H., Melake, N. A., Somily, A. M., Zakaria, A. S., Baddour, M., & Mahmoud, A. Z. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.12.007 · Cited by 26
Biofilm: A Robust and Efficient Barrier to Antifungal Chemotherapy
Souza dos Santos, A. L., & de Mello, T. P. (2015) · Journal of Antimicrobial Agents · doi:10.4172/2472-1212.1000e101 · Cited by 19
Viral protease inhibitors affect the production of virulence factors inCryptococcus neoformans
Sidrim, J. J. C., Neto, L. V. P., Cordeiro, R. D. A., Brilhante, R. S. N., Leite, J. J. G., Teixeira, C. E. C., Monteiro, A. J., Freitas, R. D. M. O. F., Ribeiro, J. F., de Mesquita, J. R. L., et al. (2012) · Canadian Journal of Microbiology · doi:10.1139/w2012-075 · Cited by 19
Wang, X., Liu, J., Chen, J., Zhang, M., Tian, C., Peng, X.-P., Li, G., Chang, W., & Lou, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104771 · Cited by 18
Ganan, M., Lorentzen, S. B., Aam, B. B., Eijsink, V. G. H., Gaustad, P., & Sørlie, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0227098 · Cited by 17
Mo, D., Li, X., Wei, L., Sun, C., Liang, H., & Cao, C. (2014) · Mycopathologia · doi:10.1007/s11046-014-9787-8 · Cited by 16
Anju, S. G., Kumar, N. S., Krishnakumar, B., & Kumar, B. S. (2015) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2015.00057 · Cited by 15
RetractedSoberón, J. R., Lizárraga, E., Sgariglia, M. A., Juárez, M. B. C., Sampietro, D. A., Altabef, A. B., Catalán, C. A. N., & Vattuone, M. A. (2015) · Antonie van Leeuwenhoek · doi:10.1007/s10482-015-0559-3 · Cited by 15
Nim, S., Rawal, M. K., & Prasad, R. (2014) · FEMS Yeast Research · doi:10.1111/1567-1364.12149 · Cited by 14
Ganan, M., Lorentzen, S. B., Gaustad, P., & Sørlie, M. (2021) · Journal of Fungi · doi:10.3390/jof7090718 · Cited by 14
Antifungal Activity of Caffeine in Combination with Fluconazole against Candida albicans
Nasrollahi, Z., & Yadegari, M. H. (2016) · Infection Epidemiology and Medicine · doi:10.18869/modares.iem.2.2.18 · Cited by 16
Şen, S., Kiraz, N., Barış, A., Turan, D., Öz, Y., Dağ, İ., & Aygün, G. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001354 · Cited by 14
Synergistic Effects of Tacrolimus and Azoles against Exophiala dermatitidis
Gao, L., Sun, Y., He, C., Zeng, T., & Li, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00948-17 · Cited by 13
Feng, W., Yang, J., Ma, Y., Xi, Z., Ren, Q., Wang, S., & Ning, H. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.11.013 · Cited by 12
Inhibition of Candida albicans growth by brominated furanones
Duo, M., Zhang, M., Luk, Y., & Ren, D. (2009) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-009-2174-6 · Cited by 12
Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans
Akins, R. A., & Sobel, J. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_29 · Cited by 15
Wibawa, T., Nurrokhman, Baly, I., Daeli, P. R., Kartasasmita, G., & Wijayanti, N. (2015) · PubMed · Cited by 12
Liu, Y., Wang, W., Yan, H., Wang, D., Zhang, M., & Sun, S. (2019) · Future Microbiology · doi:10.2217/fmb-2019-0076 · Cited by 12
Khodavaisy, S., Gharehbolagh, S. A., Abdorahimi, M., Rezaie, S., Ahmadikia, K., Badali, H., Meis, J. F. G. M., & Mahmoudi, S. (2023) · Medical Mycology · doi:10.1093/mmy/myad069 · Cited by 10
Vanhoffelen, E., Win, T. V., Braeckel, E. V., Reséndiz-Sharpe, A., Cammue, B. P. A., Lagrou, K., Thevissen, K., & Velde, G. V. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1550457 · Cited by 10
Cai, Z. J., Ding, Z., Hao, Y., Ni, T., Xie, F., Zhao, J., Li, R., Yu, S., Wang, T., Chai, X., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.053 · Cited by 11
Spader, T. B., Ramírez-Castrillón, M., Valente, P., Alves, S. H., & Severo, L. C. (2019) · Mycopathologia · doi:10.1007/s11046-019-0317-6 · Cited by 10
A Screen for Small Molecules to Target Candida albicans Biofilms
Lohse, M. B., Ennis, C. L., Hartooni, N., Johnson, A. D., & Nobile, C. J. (2020) · Journal of Fungi · doi:10.3390/jof7010009 · Cited by 11
Dynamic duo takes down fungal villains
Semighini, C. P., & Heitman, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900801106 · Cited by 10
Self-citationAnimal Models In Mycology: What Have We Learned Over The Past 30 Years
Kirkpatrick, W. R., Wiederhold, N. P., Najvar, L. K., & Patterson, T. F. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0126-6 · Cited by 11
Martín, V., de la Haba, R. R., López‐Cornejo, P., López‐López, M., Lebrón, J. A., Bernal, E., Baeza, N., Ruiz, S., Ostos, F. J., Bohórquez, V. M., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124593 · Cited by 10
Dhayanithi, N. B., Kumar, T. A., Kalaiselvam, M., Balasubramanian, T., & Sivakumar, N. (2012) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(12)60111-7 · Cited by 9
Drug Repurposing Strategy against Fungal Biofilms
de Mello, T. P., Silva, L. N., Ramos, L. S., Frota, H. F., Branquinha, M. H., & dos Santos, A. L. S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/156802662007200316142626 · Cited by 10
Cartón, J. D., de la Fuente, I., Sevillano, E., Jauregizar, N., Quindós, G., Eraso, E., & Guridi, A. (2025) · Journal of Fungi · doi:10.3390/jof11020133 · Cited by 9
Insights into the role of sphingolipids in antifungal drug resistance
Kalra, S., Tanwar, S., & Bari, V. K. (2023) · Fungal Biology Reviews · doi:10.1016/j.fbr.2023.100342 · Cited by 8
Antifungal activity of nontraditional antifungal agents
Judd, W. R., & Martin, C. A. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0012-z · Cited by 9
Juin, C., Perrin, F., Puy, T., Bernard, C., Mollichella, M.-L., Girardot, M., Costa, D., Guillard, J., & Imbert, C. (2019) · Medical Mycology · doi:10.1093/mmy/myz087 · Cited by 8
Tacrolimus as Antifungal Agent
Antypenko, L., Meyer, F., Sadykova, Z., Garbe, L., & Steffens, K. (2019) · Acta chimica slovenica · doi:10.17344/acsi.2018.4723 · Cited by 7
Jain, T., Mishra, P., Kumar, S., Panda, G., & Banerjee, D. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.994873 · Cited by 8
Nim, S., Baghel, P., Tran‐Nguyen, V., Pérès, B., Nguyen, K.-A., Pietro, A. D., Falson, P., Prasad, R., & Boumendjel, A. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0081 · Cited by 10
From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms
Pierce, C. G., Srinivasan, A., Ramasubramanian, A. K., & Lopez-Ribot, J. L. (2015) · ASM Press eBooks · doi:10.1128/9781555817466.ch19 · Cited by 8
Candida albicans Biofilms, Heterogeneity and Antifungal Drug Tolerance
LaFleur, M. D. (2011) · The Open Mycology Journal · doi:10.2174/1874437001105010021 · Cited by 9
Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs
Nett, J. E., & Andes, D. R. (2015) · ASM Press eBooks · doi:10.1128/9781555817466.ch2 · Cited by 7
Self-citationHow Promising are Combinatorial Drug Strategies in Combating Candida Albicans Biofilms?
Thevissen, K. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0127 · Cited by 6
Lukumay, N. R., Li, Y., Wang, H., & Wei, W. (2025) · Virulence · doi:10.1080/21505594.2025.2569624 · Cited by 8
Pacemaker-related Candida parapsilosis fungaemia in an immunosuppressed renal transplant recipient
Hebert, J., Barr, E., & Magee, C. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242917 · Cited by 5
Chronic Fungal Infection, Up-to-date
Kakeya, H., IMAMURA, S., Miyazaki, T., Izumikawa, K., Yamamoto, Y., Tashiro, T., & Kohno, S. (2011) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.85.333 · Cited by 5
Sousa, I. S., Tavares, L. F. S., Silva, B. A., Moreno, D. S. A., Alviano, C. S., dos Santos, A. L. S., & Kneipp, L. F. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01463-2 · Cited by 5
Scott, J., & Amich, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00059-8 · Cited by 5
Biofilm Formation in Candida albicans
Finkel, J. S., & Mitchell, A. P. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch19 · Cited by 5
In Vivo Candida Device Biofilm Models
Andes, D. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_7 · Cited by 5
Self-citationThe Role of Biofilm Matrix in Mediating Antifungal Resistance
Nett, J. E., & Andes, D. R. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_20 · Cited by 4
Self-citationInnovative Physical Approaches for Onychomycosis: Peeling, Lasers and Beyond
Sonthalia, S., & Goldust, M. (2019) · Skin Appendage Disorders · doi:10.1159/000497044 · Cited by 2
Ellagic Acid Combined with Tacrolimus Showed Synergistic Cell Growth Inhibition in Fission Yeast
Hagihara, K., Hosonaka, K., HOSHINO, S., Iwata, K., OGAWA, N., Satoh, R., Takasaki, T., Maeda, T., & Sugiura, R. (2022) · Biocontrol Science · doi:10.4265/bio.27.31 · Cited by 2
Microevolution of Antifungal Drug Resistance
Cowen, L. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_19-1 · Cited by 2
Candida Albicans Biofilm as a Clinical Challenge
Jadhav, A. K., & Karuppayil, S. M. (2017) · Springer eBooks · doi:10.1007/978-981-10-4768-8_13 · Cited by 3
Insights in Antifungal Drug Discovery
Gay‐Andrieu, F., May, J. P., Li, D., Sun, N., Chen, H., Calderone, R., & Alex, D. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch24 · Cited by 2
Ezeokoli, O. T., Nkomo, N. P., Gcilitshana, O. M. N., & Pohl, C. H. (2023) · Springer eBooks · doi:10.1007/978-981-19-9167-7_5 · Cited by 1
Factors Affecting Drug Resistance and Virulence in Fungal Pathogen
Sharma, P., Kumari, D., Kumari, P., Kumar, A., & Pasrija, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_7 · Cited by 2
Inhibition of calcineurin as a strategy for biofilm control: Trichosporon spp. as a case study
da Silva, B. N., de Andrade, A. R. C., Lopes, F. E. S., Aguiar, A. L. R., Portela, F. V. M., Silva, M. L., Vasconcelos, B. M., Sidrim, J. J. C., Castelo‐Branco, D. D. S. C. M., & Cordeiro, R. D. A. (2025) · Biofouling · doi:10.1080/08927014.2025.2492712 · Cited by 1
Singh, D., Brink, J., Hiebner, D., & Casey, E. D. (2026) · Biofilm · doi:10.1016/j.bioflm.2026.100353 · Cited by 2
Lin, S., Huang, Y., Huang, H., Hung, W., Tseng, Y.-T., & Lu, P. (2026) · Mycoses · doi:10.1111/myc.70217 · Cited by 1
Finkina, E. I., Shevchenko, O. V., Gerasimova, А. А., Fateeva, S. I., Баландин, С. В., & Ovchinnikova, T. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188141 · Cited by 1
Pierce, C. G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A. K., & Lopez-Ribot, J. L. (2014) · Springer series on biofilms · doi:10.1007/978-3-642-53833-9_13 · Cited by 1
Self-citationReversing Antifungal Drug Resistance using Natural Plant Products
Manzoor, N. (2015) · Transcriptomics Open Access · doi:10.4172/2329-8936.1000e109 · Cited by 1
Multidrug Resistance in Fungi: The Role of Pleiotropic Drug Resistance Genes
Sharma, S., & Ganesan, K. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_8 · Cited by 1
[Advances in the study of synergistic effect of anti-biofilm agents].
Wang, C., & Cheng, H. (2012) · PubMed · Cited by 1
Clinical Implications of Candida Biofilms
Bernardo, S. M., Ilieva, V. P., Walraven, C. J., & Lee, S. A. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0302-9 · Cited by 3
Metadata
- Authors
- Uppuluri, P., Nett, J., Heitman, J., & Andes, D.
- Affiliations
- Duke Medical Center (US)
- University of Wisconsin–Madison (US)
- Corresponding author
- Heitman, Joseph
- Andes, David
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-03
- Volume
- 52
- Issue
- 3
- Pages
- 1127-1132
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2258509
- OpenAlex
- W2127992552
- Cited by
- 228
- References
- 40
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 5 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 14 · 2015: 19 · 2014: 16 · 2013: 17 · 2012: 18
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NIH-R01)
- Department of Biology, Duke University
- National Heart, Lung, and Blood Institute (T32HL007899)
- National Institute of Allergy and Infectious Diseases (R01AI042159, R01AI42159, R01 AI50438, R01AI050438)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- Candida albicans, biofilm, calcineurin, calcineurin inhibitors, FK506, cyclosporine, fluconazole, drug synergy, antifungal resistance, azole antifungals, ergosterol biosynthesis, membrane perturbation, FKBP12, catheter-related infection, combination therapy
- MeSH terms
- Animals, Antifungal Agents, Candida albicans, Drug Synergism, Humans, Microbial Sensitivity Tests, Fluconazole, Tacrolimus, Cyclosporine, Biofilms, Drug Resistance, Fungal, Rats, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.